Frequent adverse events during prolonged Bedaquiline treatment on XDR-tuberculosis patients

<b>Background:</b> Drug resistance tuberculosis is a global health problem. Many countries are using Bedaquilinе for the treatment of XDR-tuberculosis. <b>Aim of the study:</b> Сomparing the frequency of adverse events (АЕ) on XDR-tuberculosis patients with a standard and prolonged course of treatment. <b>Methods:</b> Prospective study from 2012 to 2018. 148 patients diagnosed with XDR-tuberculosis pulmonary were treated with Bedaquiline. 28 patients had bilateral destruction in the lungs, prolonged bacterial excretion, a prolonged course was applied to them Bedaquiline 44-48 weeks (group 1). 120 patients received a standard (24 weeks) course Bedaquiline(group 2). All patients received basic regiment for 24 months. The frequency of all AE, which during the course Bedaquiline treatment in patients of groups 1 and 2 regardless of the connection with its reception. <b>Results:</b> Patients of group 1 had АЕ: eosinophilia -11 cases (39,3%), arthralgia-10(35,7%), diarrhea-7(25%), nausea-6(21,4%), elevation uric acid-4 (14,3%), interval lengthening QT-2 (7,1%), elevation transaminase-1 (3,6%). Patients of the 2 groups were АЕ: eosinophilia–46 cases (38,3%)(р1-2&gt;0,1), arthralgia–52(43,3%)(р1-2&gt;0,1), nausea–34 (28,3%)(р1-2&gt;0,1), diarrhea–29(24,2%)(р1-2&gt;0,1), elevation uric acid–20(16,7%)(р1-2&gt;0,1), interval lengthening QT–11(9,2%)(р1-2&gt;0,1), elevation transaminase–23 (19,2%)(р1-2&lt;0,05). Also, patients of the 2nd group had: headache–32(26,7%), skin rash–18(15%), anxiety–18(15%), sensorineural hearing loss–14(11,7%). No AE required the abolition of basic treatment. <b>Conclusions:</b> the frequency of AE in patients with prolonged and standard treatment with Bedaquiline did not differ significantly